Put companies on watchlist
Vita 34 AG
ISIN: DE000A0BL849
WKN: A0BL84
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Vita 34 AG · ISIN: DE000A0BL849 · EQS - adhoc news (54 News)
Country: Germany · Primary market: Germany · EQS NID: 1736107
27 September 2023 07:21PM

A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor


EQS-Ad-hoc: Vita 34 AG / Key word(s): Legal Matter
Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor

27-Sep-2023 / 19:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


 

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

 

A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor

Leipzig, [27 Sept 2023] – Polski Bank Komórek Macierzystych (“PBKM”), a fully owned subsidiary of Vita 34 AG announced on January 2, 2020, that PBKM´s subsidiary FamiCordTx S.A. entered into an agreement to acquire from a US-based biotech company (“Licensor”), an exclusive license to use CAR-T technology (“CAR-T Licence”). Based on this license, FamiCordTx intended to develop a project to market cancer immunotherapy (“Project”).

FamiCordTx  has obtained information that Licensor cannot grant the CAR-T Licence to FamiCordTx to the extent required for the Project. FamiCordTx (along with the PBKM  which joined as a party the license agreement on May 12, 2020),  decided today to file a lawsuit against Licensor. FamiCordTx and PBKM will take all legal steps under both the license agreement with Licensor and the applicable US law to enforce its rights, including, in further steps, possible claims for damages.

There exist alternative technologies which FamiCordTx can use to develop the aforementioned  Project to market cancer immunotherapy. FamiCordTx is in discussions with relevant parties including the Licensor in order to conclude agreements to use such technologies.

If FamiCordTx is not able to substitute the CAR-T License by an alternative technology FamiCordTx is required to develop this technology by itself which requires FamiCordTx to raise additional funds and which will delay the development of CAR-T based technology.

Notifying person: Jakub Baran (CEO)



End of Inside Information

27-Sep-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1736107

 
End of Announcement EQS News Service

1736107  27-Sep-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1736107&application_name=news&site_id=boersengefluester
Visual performance / price development - Vita 34 AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.